As a clonal plasma cell abnormal proliferative tumor in the bone marrow, MM is accompanied by the secretion of large amounts of M proteins and is highly heterogeneous, leading to symptoms such as hypercalcemia, renal damage, anemia, bone destruction, and pathological clinical signs (Yanai et al., 2012; Corre et al., 2021). Here, MYOM2 is linked to anemia (phenotype).